Table 1. Baseline demographics of patients with prostate cancer who underwent radical prostatectomy according to BMI.
| Variable | Non-obese group (BMI<25 kg/m2) (n=25) | Obese group (BMI≥25 kg/m2) (n=37) | p-value |
|---|---|---|---|
| Age at surgery (y) | 68 (63.5~73.0) | 64 (60.0~67.0) | 0.009 |
| BMI (kg/m2) | 23.0 (21.5~24.3) | 26.7 (25.7~27.6) | <0.001 |
| Diabetes | 4 (16.0) | 6 (16.2) | 0.982 |
| Total cholesterol (mg/dL) | 165.0 (151.0~182.7) | 181.0 (161.0~201.0) | 0.061 |
| Adipokine | |||
| Adiponectin (µg/mL) | 7.72 (5.12~9.57) | 5.52 (4.00~9.32) | 0.005 |
| Leptin (ng/mL) | 6.80 (4.40~9.60) | 11.40 (6.60~7.75) | 0.004 |
| IL-6 (pg/mL) | 1.40 (0.93~3.48) | 1.24 (0.95~1.75) | 0.294 |
| IGF-1 (ng/mL) | 132.40 (111.25~175.45) | 141.10 (112.40~165.75) | 0.869 |
| Resistin (ng/mL) | 8.41 (5.41~11.58) | 8.26 (6.13~11.19) | 0.785 |
| CXCL10 (pg/mL) | 122.98 (103.78~153.65) | 121.70 (109.69~166.32) | 0.581 |
| Chemerin (×103) (pg/mL) | 74.0 (59.35~88.14) | 74.95 (65.56~82.31) | 0.791 |
| Serum PSA level (ng/mL) | 6.90 (4.72~13.24) | 11.00 (6.10~15.49) | 0.209 |
| Prostate volume (total) (mL) | 32.70 (28.95~38.05) | 40.10 (27.80~47.00) | 0.080 |
| Clinical T stage | 0.387 | ||
| ≤T2 | 24 (96.0) | 32 (86.5) | |
| ≥T3 | 1 (4.0) | 5 (13.5) | |
| Biopsy GS | 0.037 | ||
| ≤6 | 10 (40.0) | 5 (13.5) | |
| 7 | 12 (48.0) | 21 (56.8) | |
| ≥8 | 3 (12.0) | 11 (29.7) | |
| Pathologic T stage | 0.042 | ||
| ≤pT2 | 21 (84.0) | 22 (59.5) | |
| ≥pT3 | 4 (16.0) | 15 (40.5) | |
| Pathologic GS | 0.304 | ||
| ≤6 | 1 (4.0) | 0 (0) | |
| 7 | 20 (80.0) | 27 (73.0) | |
| ≥8 | 4 (16.0) | 10 (27.0) | |
| EPE | 4 (16.0) | 15 (40.5) | 0.040 |
| SVI | 0 | 3 (8.1) | 0.144 |
| Positive SM | 5 (20.0) | 9 (24.3) | 0.690 |
Values are presented as median (range) or number (%).
BMI: body mass index, IL: interleukin, IGF: insulin-like growth factor, CXCL: C-X-C motif chemokine, PSA: prostate-specific antigen, GS: Gleason score, EPE: extraprostatic extension, SVI: seminal vesicle invasion, SM: surgical margin.